A Phase 1b/2a randomized double-blind placebo-controlled parallel-group dose-escalation study to investigate the safety tolerability pharmacokinetics pharmacodynamics and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies

Brief description of study

Longboard Pharmaceuticals, Inc. has begun a study of an investigational drug called LP352 as a possible treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEE). An investigational drug is one that has not been approved by regulatory agencies, such as the United States (US) Food and Drug Administration (FDA), European Union (EU) European Medicines Agency (EMA), or others.

LP352 is being studied to see if it might reduce the number of seizures in patients with developmental and epileptic encephalopathies (DEE). LP352 is thought to work by activating specific sites in the brain that are associated with seizure disorders.

The main goal of this study is to learn how well LP352 works in addition to your regular anti seizure medication and how safe different doses of LP352 are compared with placebo. A placebo is an inactive material that looks like the investigational drug but does not have any active drug. Researchers use a placebo to see if the investigational drug works better or is safer than taking nothing. In this informed consent form, “study drug” means either LP352 or placebo.


Clinical Study Identifier: s22-00365
ClinicalTrials.gov Identifier: NCT05364021


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.